304874-60-0

Basic information

• Product Name: 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-one
• Synonyms: 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-one
• CAS NO: 304874-60-0
• Molecular Weight: 271.746
• Mol File: 304874-60-0.mol

Chemical Properties

• CAS DataBase Reference: 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-one(304874-60-0)
• EPA Substance Registry System: 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-one(304874-60-0)

Safety Data

• Hazardous Substances Data: 304874-60-0(Hazardous Substances Data)

Upstream product

• 120902-45-6 5-bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 63503-60-6 3-chlorophenylboronic acid 
• 19155-24-9 3,3-dimethyloxindole 

Downstream Products

• 305832-02-4 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione 

Relevant articles and documents

New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles.

A new series of 3,3-disubstituted-5-aryloxindoles has been synthesized and evaluated for progesterone receptor antagonist (PR) activity in a T47D cell alkaline phosphatase assay and for their ability to bind PR in competition binding studies. In this comm

Indoline derivatives

This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R1and R2may be single substituents or fused to form spirocyclic rings.

CYCLIC REGIMENS UTILIZING INDOLINE DERIVATIVES

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R 1 and R 2 may be single substituents or fused to form spirocyclic rings, in combination with progestins, estrogens, or both. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

Thio-oxindole derivatives

This invention relates to compounds which are agonists of the progesterone receptor which have the general structures: wherein: R1and R2are H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; substituted aryl; heteroaryl; substituted heteroaryl; alkylaryl; alkylheteroaryl;1-propynyl; or3-propynyl; or R1and R2are joined to form an alkyl, alkenyl or heterocyclic ring; or R1and R2together comprise a double bond to CMe2; C(cycloalkyl), O, or C(cycloether); R3is H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, alkynyl, substituted alkynyl, or CORA; RAis H, C1to C3alkyl, substituted C1to C3alkyl, C1to C3alkoxy, substituted C1to C3alkoxy, C1to C3aminoalkyl, or substituted C1to C3aminoalkyl; R4is H, halogen, CN, NH2, NO2, C1to C6alkyl, or substituted C1to C6alkyl, C1to C6alkoxy, substituted C1to C6alkoxy, C1to C6aminoalkyl, or substituted C1to C6aminoalkyl; R5is optionally substituted and selected from a benzene ring, a five or six membered heterocyclic ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO2or NR6; or an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety; Q1is S, NR7, CR8R9; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.